1
项与 Prolanta(Oncolix, Inc.) 相关的临床试验Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
This trial is a Phase I open-label safety study of Prolanta™, a recombinant analog of the human prolactin protein with a single amino acid substitution to create an antagonist of the prolactin receptor. The Sponsor believes that blocking the prolactin receptor in patients with ovarian and other cancers will be effective as a monotherapy or in combination with other chemotherapies. This Phase I study will be conducted in Subjects with recurrent or persistent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
100 项与 Prolanta(Oncolix, Inc.) 相关的临床结果
100 项与 Prolanta(Oncolix, Inc.) 相关的转化医学
100 项与 Prolanta(Oncolix, Inc.) 相关的专利(医药)
100 项与 Prolanta(Oncolix, Inc.) 相关的药物交易